INM - InMed Pharmaceuticals Inc
IEX Last Trade
0.3473
0.003 0.720%
Share volume: 514,657
Last Updated: Fri 30 Aug 2024 09:59:47 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$0.34
0.00
0.73%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-10.76%
1 Month
59.51%
3 Months
17.91%
6 Months
-15.50%
1 Year
-59.67%
2 Year
-94.48%
Key data
Stock price
$0.35
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.12 - $2.08
52 WEEK CHANGE
-$0.57
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Eric Adams
Region: US
Website: https://www.inmedpharma.com/
Employees: 18
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.inmedpharma.com/
Employees: 18
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
inmed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. inmed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
Recent news